Veru To Host Investor Call On January 4th, 2024 To Discuss Recent Financing And Strategy To Prioritize The Development Of Enobosarm As A Combination Treatment To Prevent Muscle Loss And Augment Fat Loss Associated With Weight Loss GLP-1 Drugs
Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology, and viral induced acute respiratory distress syndrome, today